Shanghai, China, March 26, 2025 – Asieris Pharmaceuticals (688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announced that its latest preclinical research findings will be presented in poster format at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held from April 25th to 30th in Chicago, USA. The poster details are as follows:
Abstract: ASN-7350, a highly selective FGFR2/3 dual inhibitor, for FGFR2/FGFR3 driven solid tumors
Poster number：3014
Section：20
Poster Board Number：15
Session Date and Time: April 28, 2025, 2:00 PM – 5:00 PM
The AACR Annual Meeting is one of the oldest and largest academic conferences focused on cancer research globally. The conference highlights high-quality research and innovation in various aspects of oncology, making it a focal point for global cancer research. It gathers the most cutting-edge research findings in the field of oncology. The abstract contents have been published on the official website of AACR.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
